menu
    • menu

    Company profile for GenEdit

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At GenEdit, we aim to overcome the existing limitations in genetic medicine so we can positively impact the lives of as many people as possible. GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.The foundation of our company is our NanoGalax...
    At GenEdit, we aim to overcome the existing limitations in genetic medicine so we can positively impact the lives of as many people as possible. GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles.The foundation of our company is our NanoGalaxy platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GenEditUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    681 Gateway Blvd, Suite 313, South San Francisco, California 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://genedit.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/genedit/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GenEdit Rebrands As Breezebio, Raises $60M For Genetic Drug R&D
    GenEdit Rebrands As Breezebio, Raises $60M For Genetic Drug R&D

    25 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/genedit-rewrites-identity-emerging-breezebio-60m-genetic-medicine-rd

    FIERCE PHARMA
    25 Feb 2026
    Share Share
    GenEdit Appoints Dr. Mora as CSO to Expand NanoGalaxy® Platform
    GenEdit Appoints Dr. Mora as CSO to Expand NanoGalaxy® Platform

    13 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112337557/en

    BUSINESSWIRE
    13 Nov 2024
    Share Share
    GenEdit Announces Multiyear Collaboration and License Agreement with Genentech
    GenEdit Announces Multiyear Collaboration and License Agreement with Genentech

    23 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240123633144/en

    BUSINESSWIRE
    23 Jan 2024
    Share Share
    Sarepta, GenEdit Share Progress Collaborate to Develop Gene Editing Therapeutics
    Sarepta, GenEdit Share Progress Collaborate to Develop Gene Editing Therapeutics

    01 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/01/2376680/36419/en/Sarepta-Therapeutics-and-GenEdit-Share-Progress-on-Research-Collaboration-and-Announce-Agreement-to-Develop-Gene-Editing-Therapeutics-for-Neuromuscular-Diseases.html

    GLOBENEWSWIRE
    01 Feb 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search